Autoimmune Hepatitis Market By Disease Type (Type 1 Autoimmune Hepatitis, Type 2 Autoimmune Hepatitis, Seronegative Autoimmune Hepatitis); By Treatment Type (Corticosteroids, Conventional Immunosuppressants, Biologics & Targeted Therapies, Liver Transplant Interventions); By Diagnosis & Monitoring Method (Autoantibody Testing, IgG Quantification, Liver Function Testing, Liver Biopsy, Fibrosis Assessment Tools); By End User (Tertiary Care Hospitals, Specialty Clinics, Diagnostic Laboratories, Transplant Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Autoimmune Hepatitis Market: Lifelong Immunosuppression and Steroid-Sparing Innovation Expand a Focused Rare-Disease Opportunity

The Global Autoimmune Hepatitis Market is estimated at USD 183.99 million in 2025 and is projected to reach USD 228.13 million by 2032, expanding at a CAGR of 3.12% during 2026–2032, according to Strategic Market Research.

 

The market is supported by recurring demand for immunosuppressive medicines, liver-function monitoring, antibody testing, specialist consultations, treatment-toxicity management, hospitalization, and advanced liver care. Autoimmune hepatitis, or AIH, is a chronic immune-mediated liver disease in which uncontrolled inflammation can progress to fibrosis, cirrhosis, liver failure, transplantation, or premature death. Clinical presentation ranges from abnormal liver tests without obvious symptoms to acute severe hepatitis, creating different levels of diagnostic and treatment intensity across the patient population.

 

A comprehensive global systematic review and meta-analysis has estimated the annual incidence to be 1.28 cases per 100,000 person-years, with a prevalence of 15.65 cases per 100,000 individuals.

 

When this pooled prevalence rate is applied to the current global population, it suggests a patient population of roughly 1.28 million individuals. There is significant geographic variation, as diagnosis is influenced by factors such as access to specialists, testing methodologies, awareness of the disease, and the quality of national healthcare databases. The underlying epidemiology, treatment outcomes, care-setting utilization, clinical segmentation, and commercial patient funnel support a market centered on chronic management rather than short-duration treatment.

 

A Small Patient Pool Generates Several Distinct Revenue Pathways

AIH affects all ages and ethnic groups, although women account for most diagnosed patients. In a 2025 U.S. health-system cohort of 1,129 confirmed patients, women represented approximately 80% of the population, making female patients the dominant demographic segment by diagnosed patient share. The cohort included White, Hispanic, Asian/Pacific Islander, and Black populations, while the sharp increase in prevalence among adults aged 75 years or older confirms that commercial planning cannot be limited to young and middle-aged women. Older patients may also enter care with osteoporosis, diabetes, cardiovascular conditions, or reduced tolerance for prolonged corticosteroid exposure, increasing demand for individualized maintenance regimens and safety monitoring.

Type 1 AIH is the largest disease-type segment, accounting for approximately 80% of cases. Its patient share makes it the principal source of adult medication, antibody testing, liver-function monitoring, and specialist-care demand. Type 2 AIH represents a smaller share and is more closely associated with pediatric and younger patients, while seronegative AIH extends the diagnostic pathway through greater dependence on liver biopsy, specialist interpretation, and repeat testing.

Associated autoimmune conditions provide another route into diagnosis and long-term care. Autoimmune thyroid disease has been reported in approximately 6%–23% of AIH populations, while celiac disease occurs in roughly 3%–6%. Connections with type 1 diabetes, inflammatory bowel disease, Sjögren’s syndrome, vitiligo, Graves’ disease, and rheumatoid arthritis can lead to cross-referral between hepatologists, gastroenterologists, endocrinologists, rheumatologists, and primary-care physicians.

The patient population is commercially divided by disease status. Newly diagnosed active disease supports induction therapy and intensive laboratory follow-up. Patients in biochemical remission generate long-duration maintenance demand. Incomplete responders and patients with drug intolerance create demand for treatment switching and emerging therapies. Cirrhosis, acute severe AIH, and liver failure move spending toward hospitalization, complication management, and transplantation. Relapse after treatment withdrawal returns patients to active pharmacological management. Market revenue can therefore rise steadily despite low prevalence because a single patient may move through several treatment and care settings over many years.

 

Long-Term Immunosuppression Sustains Recurring Revenue

Corticosteroids and conventional immunosuppressants account for the largest treatment share by patient utilization. Prednisone or prednisolone, generally combined with azathioprine, remains the main first-line approach. Budesonide may be considered for selected patients without cirrhosis or acute severe disease, while mycophenolate mofetil, calcineurin inhibitors, and other immunomodulators are used when patients cannot tolerate or respond adequately to standard therapy.

Standard corticosteroid- and azathioprine-based treatment produces clinical or biochemical improvement in approximately 70%–90% of treated patients, depending on the response definition and duration of follow-up. A recent U.S. cohort reported a six-month response rate of 76%, confirming that conventional immunosuppression retains the largest treatment share while leaving a clinically important non-responder population for second-line and emerging therapies.

Treatment aims to normalize liver enzymes and immunoglobulin G rather than provide temporary symptom relief. Patients commonly remain on maintenance therapy for several years, and many require lifelong immunosuppression. A 2026 meta-analysis reported a pooled relapse rate of 51.1% among selected patients who stopped treatment after achieving remission. This means that more than half of the withdrawal-attempt segment may return to active therapy, reinforcing recurring demand for medicines, laboratory testing, specialist visits, and treatment reinitiation.

Generic corticosteroids and azathioprine limit the revenue contribution of first-line medicines despite their dominant treatment share. Market value is distributed across repeat prescriptions, blood testing, management of corticosteroid complications, specialist follow-up, and treatment switching. Premium therapies will need to demonstrate a meaningful reduction in steroid exposure, relapse, persistent biochemical activity, or liver progression to justify higher pricing against inexpensive generic regimens.

Updated clinical guidance recommends immunosuppressive treatment for active disease, including patients with advanced fibrosis or compensated cirrhosis. Greater emphasis on complete biochemical response supports more frequent laboratory monitoring and earlier treatment intensification because persistent low-level inflammation can continue to damage the liver even when symptoms improve.

 

Steroid Toxicity Creates the Highest-Value Treatment Segment

The strongest commercial opportunity lies among patients with an incomplete response, medication intolerance, repeated relapse, or unacceptable corticosteroid toxicity. Approximately 10%–20% of treated cohorts fall into the inadequate-response or intolerance segment. Although smaller than the first-line treatment population, this subsegment generates higher expenditure through second-line medicines, closer monitoring, repeat testing, fibrosis assessment, and specialist care.

Long-term corticosteroid exposure can contribute to diabetes, osteoporosis, fractures, cataracts, weight gain, infection risk, and other complications. These effects strengthen demand for therapies that preserve disease control while reducing cumulative steroid use. Developers are therefore targeting the 10%–20% difficult-to-treat share and steroid-dependent patients rather than attempting to replace generic first-line therapy across the entire market.

A U.S. cohort included 715 treated patients, of whom 547, or 76%, demonstrated treatment response at six months. The remaining 24% formed an early non-response group at greater risk of continued inflammation and treatment escalation. Delayed biochemical control increases the need for additional immunosuppressants, intensive follow-up, repeat biopsy or fibrosis evaluation, and referral to specialist centers.

Current care relies on guideline-supported use of medicines developed for other indications because a disease-specific therapy has yet to establish a leading branded treatment category in AIH. A first approved product could capture value from patients who do not achieve adequate control with conventional therapy, provided it delivers stronger biochemical response, lower steroid exposure, acceptable hepatic safety, and a manageable monitoring burden.

 

Multi-Step Diagnosis Expands Laboratory and Specialist Demand

AIH has no single diagnostic marker. Physicians combine liver enzymes, serum immunoglobulin G, antinuclear antibodies, smooth-muscle antibodies, liver-kidney microsomal antibodies, medication history, exclusion testing, imaging, and liver histology. This pathway generates demand across hospital laboratories, reference laboratories, pathology providers, imaging centers, gastroenterology practices, and hepatology clinics.

Commercial diagnostic activity continues after the initial diagnosis. Patients receiving azathioprine, corticosteroids, mycophenolate, or other immunosuppressants require repeated liver-function tests, blood counts, immunoglobulin measurements, and medication-safety monitoring. Patients with fibrosis or cirrhosis generate additional demand for imaging, portal-hypertension assessment, cancer surveillance, and management of decompensation risk.

Quest Diagnostics offers an autoimmune hepatitis panel containing antinuclear, smooth-muscle or actin, mitochondrial, and LKM-1 antibody testing. The panel consolidates several tests within one laboratory order, while specialist interpretation and liver biopsy remain important in uncertain or seronegative cases. The approximately 80% patient share held by Type 1 AIH makes ANA and smooth-muscle or actin antibody testing the largest subtype-related diagnostic pathway, while LKM-1 testing serves the smaller Type 2 population.

The diagnostic segment benefits from both patient growth and test recurrence. The estimated 8.4% CAGR in diagnosed prevalence within the cited U.S. health system between 2010 and 2019 exceeded the projected 6.4% CAGR of the overall market. This difference indicates that rising recognition can expand patient volumes even when revenue growth is moderated by generic drug pricing and uneven specialist access.

 

Advanced Disease Drives Disproportionate Healthcare Spending

Delayed diagnosis and incomplete disease control create high-cost episodes despite the rarity of AIH. Approximately 28%–33% of adults may already have cirrhosis when the disease is diagnosed, making advanced liver disease one of the largest clinically defined severity subsegments. These patients require more intensive monitoring and face higher risks of portal hypertension, ascites, variceal bleeding, hepatic decompensation, liver cancer, hospitalization, and transplantation.

U.S. AIH-related hospital admissions increased from approximately 20,984 in 2016 to 22,680 in 2019, representing an estimated CAGR of 2.6%. Aggregate inpatient costs reached approximately USD 387.25 million in 2019. Hospitalization therefore represents a major expenditure pool within the market, particularly among patients with acute presentation, uncontrolled inflammation, cirrhosis complications, or treatment toxicity.

A separate 2016 inpatient analysis reported that approximately 1.5% of AIH-related hospitalized patients underwent liver transplantation and 3.8% died during hospitalization. These small shares represent the most severe and resource-intensive patient groups, requiring transplant-center care, complex inpatient management, and prolonged post-discharge monitoring.

Liver transplantation is reserved for acute liver failure, decompensated cirrhosis, or progression that cannot be controlled medically. AIH has historically accounted for approximately 4%–6% of liver transplants in North America. Applying this share to 10,125 adult U.S. liver transplants in 2023 indicates approximately 405–608 AIH-associated procedures.

Transplantation also creates recurring post-procedure demand. Recipients require lifelong immunosuppression, graft monitoring, laboratory testing, hospital follow-up, and management of infection and recurrence risks. Hospitals and transplant centers therefore manage a smaller patient share but capture much higher expenditure per patient than routine outpatient care.

 

Biologic Development Repositions Competition Around Steroid Reduction

The emerging pipeline is moving beyond broad immunosuppression toward therapies that target B cells or selected immune pathways. Amgen registered a Phase 2/3 study of inebilizumab in May 2026. The program is designed to evaluate safety, tolerability, dose selection, disease activity, and glucocorticoid use, placing steroid reduction at the center of its clinical and commercial positioning.

Ianalumab, a B-cell activating factor receptor inhibitor, has been evaluated in patients with an incomplete response or intolerance to standard treatment. Inebilizumab and ianalumab indicate that B-cell modulation is becoming one of the principal competitive approaches for the 10%–20% difficult-to-treat segment.

Zetomipzomib produced positive Phase 2a PORTOLA results in relapsed or refractory AIH, but its development also demonstrates the regulatory demands of testing medicines in patients with liver impairment. Kezar’s regulatory interactions focused on the design, endpoints, hepatic pharmacokinetics, and monitoring requirements for a potential registration-enabling AIH program.

Aurinia Pharmaceuticals acquired Kezar in May 2026 through a cash and contingent-value-right structure. The transaction preserved the strategic value of zetomipzomib while transferring its development, financing, and regulatory risk to an autoimmune-focused pharmaceutical company.

 

Competitive and Regional Market Positioning

The competitive ecosystem includes generic pharmaceutical suppliers, specialty laboratories, hospital and pathology networks, transplant centers, professional societies, and biotechnology companies developing disease-focused therapies. Generic manufacturers hold the largest treatment-volume share through corticosteroids and conventional immunosuppressants, while emerging developers compete for the higher-value refractory segment through steroid reduction, biochemical remission, tolerability, and prevention of fibrosis progression.

North America holds the leading regional position because the United States combines a diagnosed prevalence rate of 31.2 per 100,000—nearly twice the global pooled prevalence rate of 15.65 per 100,000—with established hepatology networks, broad laboratory access, active clinical development, and favorable conditions for orphan-drug commercialization. Europe remains central to clinical practice and product development, while Asia-Pacific represents an underdiagnosed opportunity where expansion will depend on stronger disease recognition, wider specialist access, and improved country-level epidemiological data.

Outpatient hepatology and gastroenterology clinics manage the largest patient share because most medicines are taken at home and monitored through scheduled laboratory tests. Hospitals account for the greatest expenditure per event through acute severe disease, cirrhosis complications, liver biopsy, inpatient immunosuppression, and transplantation. Reference laboratories retain recurring demand from both diagnosis and long-term treatment monitoring.

 

Autoimmune Hepatitis Market Outlook

Growth through 2032 will be supported by the overall market CAGR of 6.4%, rising diagnosed prevalence, longer treatment duration, repeated relapse management, wider use of antibody and monitoring tests, and development of steroid-sparing therapies. Generic first-line drugs and the small rare-disease population will continue to limit broad pharmaceutical revenue, directing commercial attention toward difficult-to-treat patients and premium specialist products.

Patients with persistent biochemical activity, repeated relapse, azathioprine intolerance, prolonged corticosteroid dependence, or advanced fibrosis form the most commercially attractive segment. This includes the 10%–20% inadequate-response or intolerance share, the 24% of treated patients without a six-month response in the cited U.S. cohort, and the 51.1% relapse share among selected patients attempting treatment withdrawal.

A therapy that achieves durable remission while lowering steroid exposure could shift spending from inexpensive maintenance drugs toward a disease-specific branded category. Strong adoption will depend on evidence that improved biochemical control reduces progression, hospitalization, treatment toxicity, or transplant risk.

The Autoimmune Hepatitis Market will remain a focused chronic-care ecosystem rather than a high-volume pharmaceutical category. Type 1 AIH’s approximately 80% patient share, conventional therapy’s dominant utilization position, the 10%–20% difficult-to-treat segment, and the 28%–33% cirrhosis-at-diagnosis population define where patient volume and commercial value are concentrated. Recurring immunosuppression, diagnostic complexity, specialist monitoring, hospitalization, and steroid-sparing development provide the foundation for steady market expansion.

 

Autoimmune Hepatitis Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 183.99 Million
Revenue Forecast in 2032	USD 228.13 Million
Overall Growth Rate	CAGR of 3.12% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Disease Type, By Treatment Type, By Diagnosis and Monitoring Method, By End User, By Geography
By Disease Type	Type 1 Autoimmune Hepatitis, Type 2 Autoimmune Hepatitis, Seronegative Autoimmune Hepatitis
By Treatment Type	Corticosteroids, Conventional Immunosuppressants, Biologics and Targeted Therapies, Liver Transplant Interventions
By Diagnosis and Monitoring Method	Autoantibody Testing, IgG Quantification, Liver Function Testing, Liver Biopsy, Fibrosis Assessment Tools
By End User	Tertiary Care Hospitals, Specialty Clinics, Diagnostic Laboratories, Transplant Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Recurring demand for long-term immunosuppressive treatment and laboratory monitoring Rising diagnosis of previously unrecognized autoimmune hepatitis cases Growing need for steroid-sparing therapies among patients with intolerance or inadequate response
Customization Option	Available upon request